期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 208, 期 7, 页码 1351-1358出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20100951
关键词
-
资金
- Cancer Council of Victoria
- National Health and Medical Research Council (Canberra) [461221, 461299, 516703]
- National Institutes of Health [CA43540]
- Australian Research Council
- Leukemia and Lymphoma Society (Specialized Center of Research) [7413]
For malignant growth, solid cancers must stimulate the formation of new blood vessels by producing vascular endothelial growth factor (VEGF-A), which is required for the survival of tumor-associated vessels. Novel anticancer agents that block VEGF-A signaling trigger endothelial cell (EC) apoptosis and vascular regression preferentially within tumors, but how the ECs die is not understood. In this study, we demonstrate that VEGF-A deprivation, provoked either by drug-induced tumor shrinkage or direct VEGF-A blockade, up-regulates the proapoptotic BH3 (Bcl-2 homology 3)-only Bcl-2 family member Bim in ECs. Importantly, the tumor growth inhibitory activity of a VEGF-A antagonist required Bim-induced apoptosis of ECs. These findings thus reveal the mechanism by which VEGF-A blockade induces EC apoptosis and impairs tumor growth. They also indicate that drugs mimicking BH3-only proteins may be exploited to kill tumor cells not only directly but also indirectly by ablating the tumor vasculature.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据